Skip to content
10-Q

Quarterly Report

Inhibitor Therapeutics, Inc. INTI

0001493152-25-022178

← back to feed
Filed
Nov 13, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2025 · Nov 13, 2025 172.57M sh
Stock Issued Q3 2025 · Sep 30, 2025 215K sh
Stock Issued Q3 2025 · Sep 30, 2024 290K sh
Shares Diluted Q3 2025 · Sep 30, 2025 172.57M sh
Shares Diluted Q3 2025 · Sep 30, 2025 172.49M sh
Shares Diluted Q3 2025 · Sep 30, 2024 172.32M sh
Shares Diluted Q3 2025 · Sep 30, 2024 172.24M sh
Operating Cash Flow Q3 2025 · Sep 30, 2025 −$2.63M
Operating Cash Flow Q3 2025 · Sep 30, 2024 −$2.46M
Cash And Equivalents Q3 2025 · Sep 30, 2025 $2.98M
Cash And Equivalents Q3 2025 · Dec 31, 2024 $5.61M
Stockholders Equity Q3 2025 · Sep 30, 2025 $3.45K
Stockholders Equity Q3 2025 · Jun 30, 2025 $715.64K
Stockholders Equity Q3 2025 · Mar 31, 2025 $1.35M
Stockholders Equity Q3 2025 · Dec 31, 2024 $1.99M
Stockholders Equity Q3 2025 · Sep 30, 2024 $3.41M
Stockholders Equity Q3 2025 · Jun 30, 2024 $4.14M
Stockholders Equity Q3 2025 · Mar 31, 2024 $4.64M
Stockholders Equity Q3 2025 · Dec 31, 2023 $5.28M
Current Liabilities Q3 2025 · Sep 30, 2025 $87.53K
Current Liabilities Q3 2025 · Dec 31, 2024 $709.62K
Total Liabilities Q3 2025 · Sep 30, 2025 $3.13M
Total Liabilities Q3 2025 · Dec 31, 2024 $3.71M
Current Assets Q3 2025 · Sep 30, 2025 $3.06M
Current Assets Q3 2025 · Dec 31, 2024 $5.69M
Total Assets Q3 2025 · Sep 30, 2025 $3.14M
Total Assets Q3 2025 · Dec 31, 2024 $5.69M
Eps Diluted Q3 2025 · Sep 30, 2025 $0.00
Eps Diluted Q3 2025 · Sep 30, 2025 −$0.01
Eps Diluted Q3 2025 · Sep 30, 2024 $0.00
Eps Diluted Q3 2025 · Sep 30, 2024 −$0.01
Eps Basic Q3 2025 · Sep 30, 2025 $0.00
Eps Basic Q3 2025 · Sep 30, 2025 −$0.01
Eps Basic Q3 2025 · Sep 30, 2024 $0.00
Eps Basic Q3 2025 · Sep 30, 2024 −$0.01
Sga Expense Q3 2025 · Sep 30, 2025 $363.43K
Sga Expense Q3 2025 · Sep 30, 2025 $1.17M
Sga Expense restated Q3 2025 · Sep 30, 2024 $443.58K
Sga Expense restated Q3 2025 · Sep 30, 2024 $1.3M
Rd Expense Q3 2025 · Sep 30, 2025 $377.79K
Rd Expense Q3 2025 · Sep 30, 2025 $939.47K
Rd Expense restated Q3 2025 · Sep 30, 2024 $369.62K
Rd Expense restated Q3 2025 · Sep 30, 2024 $869.76K
Net Income Q3 2025 · Sep 30, 2025 −$712.18K
Net Income Q3 2025 · Sep 30, 2025 −$2M
Net Income Q3 2025 · Jun 30, 2025 −$659.94K
Net Income Q3 2025 · Mar 31, 2025 −$632.85K
Net Income Q3 2025 · Sep 30, 2024 −$730.96K
Net Income Q3 2025 · Sep 30, 2024 −$1.92M
Net Income Q3 2025 · Jun 30, 2024 −$501.69K
Net Income Q3 2025 · Mar 31, 2024 −$684.71K
Operating Income Q3 2025 · Sep 30, 2025 −$741.22K
Operating Income Q3 2025 · Sep 30, 2025 −$2.11M
Operating Income Q3 2025 · Sep 30, 2024 −$813.2K
Operating Income Q3 2025 · Sep 30, 2024 −$2.17M